/wp-content/uploads/iEcure_logo.png00eallison/wp-content/uploads/iEcure_logo.pngeallison2025-03-24 17:51:022025-03-26 18:08:48(P008) A First in Human, Single Arm, Open Label Phase 1/2 Study Evaluating ECUR-506 in Neonatal OTC Deficiency: Initial Observations
/wp-content/uploads/iEcure_logo.png00David Anderson/wp-content/uploads/iEcure_logo.pngDavid Anderson2025-03-21 09:06:012025-03-21 09:06:01iECURE Announces Presentation of Full Data for the First Infant Dosed with ECUR-506 in OTC-HOPE Phase 1/2 Clinical Trial at the 2025 ACMG Annual Clinical Genetics Meeting
/wp-content/uploads/iEcure_logo.png00David Anderson/wp-content/uploads/iEcure_logo.pngDavid Anderson2025-03-11 19:35:012025-03-11 19:35:01iECURE to Present Initial Data from Phase 1/2 OTC-HOPE Clinical Trial in Ornithine Transcarbamylase Deficiency at ACMG Annual Clinical Genetics Meeting
https://iecure.com/wp-content/uploads/Science_logo.png52280eallison/wp-content/uploads/iEcure_logo.pngeallison2025-01-30 17:53:142025-01-30 18:02:36Gene editor may have cured infant of a deadly metabolic disorder
https://iecure.com/wp-content/uploads/endpoint-news.svg52280eallison/wp-content/uploads/iEcure_logo.pngeallison2025-01-30 17:45:212025-01-30 17:48:21Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago
/wp-content/uploads/iEcure_logo.png00eallison/wp-content/uploads/iEcure_logo.pngeallison2025-01-08 19:08:512025-01-09 16:28:06iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency
https://iecure.com/wp-content/uploads/philadelphia-logo.svg00eallison/wp-content/uploads/iEcure_logo.pngeallison2024-05-29 17:19:002024-05-29 17:46:01University of Pennsylvania gene-editing spinout iEcure hits the FDA trifecta
/wp-content/uploads/iEcure_logo.png00David Anderson/wp-content/uploads/iEcure_logo.pngDavid Anderson2024-05-07 05:00:362024-05-07 08:06:38iECURE Receives FDA Fast Track Designation for ECUR-506 for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
https://iecure.com/wp-content/uploads/endpoint-news.svg52280eallison/wp-content/uploads/iEcure_logo.pngeallison2024-04-12 15:36:162024-04-12 15:49:23Exclusive: Jim Wilson startup gets FDA green light for first test of gene editing in babies
